Product information and disease descriptionProduct descriptionProduct information
Dosage forms and strengths
6 evidence topics · 5 sources
Commercial dosage form and strength
No evidence found.
Capsules given fasted in the phase 1/2 monotherapy study
“All patients received oral palazestrant capsules once daily, continuously in 28-day treatment cycles. In this first-in-human study, patients were required to fast for 2 h prior to and 1 h after each palazestrant dose.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Capsule formulation and gastrointestinal events; tablet formulation in ongoing studies
“the drug was administered in a relatively large capsule formulation, each of which could have contributed to an increased incidence of gastrointestinal events. Ongoing studies are using a tablet formulation, allowing drug administration in the fed state, and using anti-emetic medications when needed that may reduce frequency of nausea, vomiting, and fatigue” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote